These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

67 related items for PubMed ID: 15050168

  • 1. Lymphoplasmacytic hyperplasia (possibly pre-PTLD) has varied expression and appearance in intestinal transplant recipients receiving Campath immunosuppression.
    Ruiz P, Soares MF, Garcia M, Nicolas M, Kato T, Mittal N, Nishida S, Levi D, Selvaggi G, Madariaga J, Tzakis A.
    Transplant Proc; 2004 Mar; 36(2):386-7. PubMed ID: 15050168
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period.
    Zanfi C, Lauro A, Cescon M, Dazzi A, Ercolani G, Grazi GL, Zanello M, Vivarelli M, Del Gaudio M, Ravaioli M, Cucchetti A, Vetrone G, Tuci F, Di Gioia P, Lazzarotto T, D'Errico A, Bagni A, Faenza S, Siniscalchi A, Pironi L, Pinna AD.
    Transplant Proc; 2010 Mar; 42(1):35-8. PubMed ID: 20172276
    [Abstract] [Full Text] [Related]

  • 4. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period.
    Lauro A, Amaduzzi A, Dazzi A, Ercolani G, Zanfi C, Golfieri L, Grazi GL, Vivarelli M, Cescon M, Varotti G, Del Gaudio M, Ravaioli M, Siniscalchi A, Faenza S, D'Errico A, Di Simone M, Pironi L, Pinna AD.
    Dig Liver Dis; 2007 Mar; 39(3):253-6. PubMed ID: 17275428
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Post-transplant lymphoproliferative disorders after live donor renal transplantation.
    Jain M, Badwal S, Pandey R, Srivastava A, Sharma RK, Gupta RK.
    Clin Transplant; 2005 Oct; 19(5):668-73. PubMed ID: 16146560
    [Abstract] [Full Text] [Related]

  • 7. Analysis of risk factors for the development of posttransplant lymphoprolipherative disorder among 119 children who received primary intestinal transplants at a single center.
    Quintini C, Kato T, Gaynor JJ, Ueno T, Selvaggi G, Gordon P, McLaughlin G, Tompson J, Ruiz P, Tzakis A.
    Transplant Proc; 2006 Oct; 38(6):1755-8. PubMed ID: 16908272
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Posttransplant lymphoproliferative disorder.
    Everly MJ, Bloom RD, Tsai DE, Trofe J.
    Ann Pharmacother; 2007 Nov; 41(11):1850-8. PubMed ID: 17940127
    [Abstract] [Full Text] [Related]

  • 10. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.
    Younes BS, McDiarmid SV, Martin MG, Vargas JH, Goss JA, Busuttil RW, Ament ME.
    Transplantation; 2000 Jul 15; 70(1):94-9. PubMed ID: 10919581
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Rituximab as treatment of posttransplant lymphoproliferative disorder in patients who underwent small bowel/multivisceral transplantation: report of three cases.
    Codeluppi M, Cocchi S, Guaraldi G, Di Benedetto F, Bagni A, Pecorari M, Gennari W, Pinna AD, Gerunda GE, Esposito R.
    Transplant Proc; 2005 Jul 15; 37(6):2634-5. PubMed ID: 16182770
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S, Renner C, Hammer M, Abdul-Khaliq H, Lehmkuhl HB, Berger F, Hetzer R, Reinke P.
    J Heart Lung Transplant; 2008 Jan 15; 27(1):100-5. PubMed ID: 18187094
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Lymphoproliferative disorders and de novo malignancies in intestinal and multivisceral recipients: improved outcomes with new outlooks.
    Abu-Elmagd KM, Mazariegos G, Costa G, Soltys K, Bond G, Sindhi R, Green M, Jaffe R, Wu T, Koritsky D, Matarese L, Schuster B, Martin L, Dvorchik I, Nalesnik MA.
    Transplantation; 2009 Oct 15; 88(7):926-34. PubMed ID: 19935465
    [Abstract] [Full Text] [Related]

  • 18. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
    Muti G, Cantoni S, Oreste P, Klersy C, Gini G, Rossi V, D'Avanzo G, Comoli P, Baldanti F, Montillo M, Nosari A, Morra E, Cooperative Study Group on PTLDs.
    Haematologica; 2002 Jan 15; 87(1):67-77. PubMed ID: 11801467
    [Abstract] [Full Text] [Related]

  • 19. Rising incidence of post-transplant lymphoproliferative disease in kidney transplant recipients.
    Libertiny G, Watson CJ, Gray DW, Welsh KI, Morris PJ.
    Br J Surg; 2001 Oct 15; 88(10):1330-4. PubMed ID: 11578286
    [Abstract] [Full Text] [Related]

  • 20. Campath-1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3-year follow-up.
    Muñoz AS, Cabanayan-Casasola CB, Danguilan RA, Padua FB, Ona ET.
    Transplant Proc; 2008 Sep 15; 40(7):2230-3. PubMed ID: 18790200
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.